(Q44558681)

4 December 2017

0 references

Biosimilars to treat inflammatory arthritis: the challenge of proving identity (English)

1 reference

4 December 2017

0 references

Jonathan Kay

1

0 references

Josef S Smolen

series ordinal

2

object named as

Josef S Smolen

1 reference

4 December 2017

language of work or name

English

0 references

publication date

29 July 2013

1 reference

Annals of the Rheumatic Diseases

4 December 2017

published in

1 reference

4 December 2017

volume

72

1 reference

4 December 2017

issue

10

1 reference

4 December 2017

page(s)

1589-1593

1 reference

The role of biosimilars in the treatment of rheumatic diseases

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

The advent of biosimilar therapies in rheumatology—“O Brave New World”

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-203198

10.1136/ANNRHEUMDIS-2012-203198

21 January 2018

Identifiers

DOI

1 reference

4 December 2017

1 reference